The claim wasn't that Ebolacide 2 testing was sure to result in a completely successful test of a viricide against Ebola. The claim was that there was very ilttle risk in doing the testing.
What many (including myself) claimed was that failure of Ebolacide would put the entire platform in question, and make company claims about rapid response and ease of new treatment development suspect.
I believe that is exactly what happened and is certainly part of the decline from the time your trusted associate made the claim until now. From $3 to under a buck.
Meanwhile, "my trusted associate" (one of them) warned that Seymour was concerned the shape of the virus would make Ebolacide a failure. "Shape" was the nontechnical term, but as usual my source was dead-on balls-accurate right on the money.
Anybody wise enough to listen were spared massive financial pain.
News 
Market Data 
Discover 
